Fresenius Kabi and Kit Check Collaborate on RFID Compatibility

LAKE ZURICH, Ill. and WASHINGTON, December 9, 2020 - Fresenius Kabi and Kit Check today announced the companies have entered into an agreement under which Fresenius Kabi +RFID™ medications will be read by the Kit Check inventory management solution. The collaboration signals both companies' commitment to medication safety and quality patient care across the health care continuum.

"Our partnership with Kit Check will allow hospital pharmacists to have increased visibility into how +RFID medications are being used within their institutions, which will enable them to create a safer, more efficient environment for patients and providers," said John Ducker, president and CEO of Fresenius Kabi USA. "Fresenius Kabi is committed to supporting such care environments and we are excited to work with another company that shares these values and is working toward a streamlined pharmaceutical supply chain."

Kit Check's medication management solutions enable hospital pharmacists to easily track drugs throughout their facilities and removes the workload associated with expired drugs and recalls. The company is a leader in the radio-frequency identification (RFID) space and currently holds 90 percent of the unit-dose RFID market in U.S. hospitals. By increasing medication visibility across the drug supply chain and providing downstream visibility for hospital pharmacies, Kit Check's solutions help ensure that the right drug is in the right place at the right time.

"We are delighted to be partnering with Fresenius Kabi as part of our ongoing mission to increase interoperability across the pharmaceutical supply chain," said Kevin MacDonald, CEO and co-founder of Kit Check. "By tracking the company's +RFID medications and storing the information in our cloud-based registry, we are reaffirming our commitment to offering the highest level of quality, efficiency and safety through solutions that streamline operations, reduce risk and protect patients, providers and personnel."

Fresenius Kabi launched the first of its many planned +RFID medications in September 2020. The medications contain smart labels with embedded, high-performance RFID tags that contain the relevant data that hospitals rely on every day to immediately identify, locate and manage their inventory.

Both companies will work with Auburn University RFID Lab's ARC Program to conduct testing for tag performance and quality to comply with the high-performance standards that both companies uphold.

As part of Fresenius Kabi's collaboration with Kit Check, +RFID medications, beginning with the anesthetic Diprivan^® (propofol), will be able to be read in the Kit Check system, allowing customers to access all of the relevant information for reliable product tracking. In 2021, Fresenius Kabi expects to add more than 20 medicines to its +RFID portfolio in the United States. To learn more about +RFID, please visit www.plusRFID.com.